Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. lowered its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 53.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,607 shares of the company's stock after selling 76,531 shares during the period. Ameriprise Financial Inc. owned about 0.11% of Health Catalyst worth $478,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in Health Catalyst in the fourth quarter worth about $29,000. Aquatic Capital Management LLC bought a new position in Health Catalyst in the fourth quarter worth about $63,000. Stoneridge Investment Partners LLC bought a new stake in shares of Health Catalyst during the fourth quarter valued at approximately $77,000. Martin Worley Group bought a new stake in shares of Health Catalyst during the fourth quarter valued at approximately $78,000. Finally, OneAscent Financial Services LLC bought a new stake in shares of Health Catalyst during the fourth quarter valued at approximately $97,000. Institutional investors own 85.00% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HCAT shares. Royal Bank of Canada cut their price target on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a report on Thursday, February 27th. Stephens cut their price target on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. KeyCorp cut their price target on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Citigroup cut their price target on Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a report on Friday, April 25th. Finally, Stifel Nicolaus lifted their price target on Health Catalyst from $5.00 to $5.50 and gave the company a "hold" rating in a report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Health Catalyst Price Performance

NASDAQ:HCAT traded up $0.26 during midday trading on Friday, hitting $4.10. 2,097,404 shares of the stock were exchanged, compared to its average volume of 604,212. Health Catalyst, Inc. has a one year low of $3.49 and a one year high of $9.24. The company has a market capitalization of $285.36 million, a price-to-earnings ratio of -3.04 and a beta of 1.53. The business has a 50-day moving average price of $3.95 and a two-hundred day moving average price of $5.34. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.